1.
Semin Oncol
; 17(6 Suppl 9): 47-51, 1990 Dec.
Article
in English
| MEDLINE
| ID: mdl-2259926
ABSTRACT
Megestrol acetate was administered as first-line therapy to 152 patients with advanced breast cancer. Forty-three of 136 evaluable patients (32%) obtained an objective response (95% confidence interval, 24% to 40%). Toxicity was minimal, with only 4 patients requiring dose reduction. Megestrol acetate is an effective, well-tolerated agent in previously untreated patients with advanced breast cancer.